Illustrated header graphic reading 39 Compliance Actions in 2026, Is Your Ad Agency Watching, showing two animated avatar characters, one holding a magnifying glass over a clipboard with a warning icon and another pointing at a shield with a checkmark

39 Supplement Ad Enforcement Actions in 2026: What FDA, FTC, and UK ASA Are Really Cracking Down On

November 01, 2026

Regulators did not slow down in 2026.

Between January 1 and October 22, the FDA, the FTC, and the UK's Advertising Standards Authority (ASA) took 39 formal actions against supplement companies.

That is roughly one enforcement action every eight days.

If you run paid ads for a supplement brand, this is not background noise. It is the clearest signal you will get this year about what regulators actually care about, and what your ad agency should already be checking before your creative ever goes live.

Quick Look

39 enforcement actions across FDA, FTC, and UK ASA from January through October 22, 2026.

18 FDA warning letters, most citing disease or drug claims, sometimes paired with manufacturing violations.

4 FTC actions against 2 companies, both involving children's and mental health claims.

17 ASA rulings upheld in the UK, including menopause, PCOS, and GLP-1 comparison claims.

On October 20, the FDA also finalized new guidance on how new ingredients get cleared. More on that below.

The Scoreboard: Who Got Hit, and For What

Here is the breakdown by regulator. These are public enforcement records, not allegations we are making ourselves.

Regulator Actions Main Issue
FDA (US) 18 warning letters Disease or drug claims, often with CGMP manufacturing issues
FTC (US) 4 actions, 2 companies Children's health claims and mental health claims
ASA (UK) 17 upheld rulings Hormone, menopause, and GLP-1 comparison claims

Of the 18 FDA letters, 11 cited disease or drug claims, either alone or combined with other issues. Five paired disease claims with manufacturing violations. Two involved undeclared drug ingredients hidden in a "supplement." Two more flagged new ingredients launched without enough safety data behind them.

One of those new-ingredient letters targeted a product marketed as a "GLP-1 biomimetic." That phrase alone was enough to draw scrutiny.

What Is Actually Triggering These Letters

The pattern across all three regulators is consistent. It is rarely about the product itself.

It is almost always about what the ad, the landing page, or the product listing claims the product can do.

  1. Disease and drug claims. Saying a supplement treats, cures, or prevents a named condition.
  2. Mental health claims. One FTC target claimed its supplements helped with depression, anxiety, and ADHD. That is a drug claim in a supplement wrapper.
  3. Children's health claims. A separate FTC case involved height-growth claims aimed at kids and teens, and ended in a settlement with a final order attached.
  4. GLP-1 comparison claims. "Works like Ozempic" style language is showing up across FDA letters and ASA rulings alike.
  5. Hormone and menopause claims. A single March batch brought five ASA rulings against women's supplements making menopause or PCOS claims.
  6. New ingredients without safety data. Launching a novel ingredient before you can prove it is safe is its own category of risk, separate from the claims made about it.

Two Cases Worth Knowing

TruHeight settled with the FTC over height-growth claims aimed at children and teens. The case ended in a final order.

Amare Global faced FTC action over claims that its supplements could treat depression, anxiety, and ADHD, plus a contempt motion tied to an earlier order.

"Enforcement in 2026 is not chasing bad factories. It is chasing bad claims."

That is the real takeaway from this year's data. A clean manufacturing facility will not save a brand whose ad copy promises something the product was never approved to say.

The New Ingredient Rule You Might Have Missed

On October 20, 2026, the FDA finalized key sections of its New Dietary Ingredient (NDI) notification guidance.

In plain terms, this spells out exactly what information the FDA expects before a company introduces a new ingredient to the market. If your brand is launching anything with a novel compound, a new extract, or an ingredient blend nobody else is using yet, this guidance now sets the bar you need to clear first.

We covered the broader claims side of this in our guide to FDA structure/function claims for supplement ads, and the GLP-1 specific risks in our GLP-1 supplement ad compliance breakdown. Both are worth a read if either applies to your product line.

What This Means for Choosing (or Keeping) Your Ad Agency

Most supplement brands pick an agency based on creative quality, pricing, or a case study.

Almost none of them ask the one question that actually predicts whether their ad account survives the year: does this agency have a real claims-review process, or are they just hoping nothing gets flagged?

Based on this year's enforcement data, here are the questions worth asking before you sign anything:

  1. Who on your team reviews every ad and landing page for disease, drug, and mental health claims before it goes live?
  2. How do you handle GLP-1 comparison language, given how often it is showing up in enforcement actions right now?
  3. What is your process if we want to launch a product with a new or unusual ingredient?
  4. Do you review UGC and creator scripts the same way you review our own ad copy?
  5. Have you worked with a brand that received a warning letter or ad restriction, and what did recovery actually look like?

If an agency cannot answer these clearly, that is the red flag. Compliance is not a side service bolted onto media buying. It has to run through the creative, the claims, and the landing page from the very first draft.

It also matters more if you sell in more than one country. The FDA, the FTC, and the UK's ASA do not apply the exact same standard.

A claim that slides past one regulator can still get flagged by another. If your brand ships to both the US and the UK, your agency needs a process that checks creative against both sets of rules, not just the one you happen to be more familiar with.

Documentation matters just as much as the claim itself. A lab test (COA) on file, a substantiation file for every health claim, and a clear record of where an ingredient came from are the things that turn a warning letter into a quick clarification instead of a drawn-out investigation. Brands that keep this paperwork organized before they ever get a letter are in a completely different position than brands scrambling to find it after the fact.

This is exactly what we walk through on every eBrandX compliance audit on the first call, before a single dollar of ad spend moves. We would rather catch a risky claim in a Google Doc than in a warning letter.

Self-Audit: 5 Quick Checks

1. Does any ad or landing page name a specific disease, condition, or diagnosis?

2. Does any creative compare your product to a prescription drug, including GLP-1 medications?

3. Are any claims aimed at children, teens, or marketed around kids' health outcomes?

4. If you launched a new ingredient this year, do you have documented safety evidence on file?

5. Does your UGC and creator content go through the same claims review as your in-house ad copy?

If you answered no or not sure to more than one of these, it is worth a second look before Q4 spend ramps up.

This also ties directly into the account-level risks we broke down in our Meta ads account audit guide, since claims problems are one of the fastest ways to trigger a platform-level restriction, not just a regulatory letter.

The Bottom Line

Thirty nine actions in ten months is not a fluke. It is the new normal.

Supplement brands that win in 2026 are not the ones with the boldest claims. They are the ones whose agency treats compliance as part of the creative process, not an afterthought bolted on when something already went wrong.

If you want a second set of eyes on your current ads, claims, and landing pages, book a free strategy call with eBrandX. We will tell you exactly where the risk sits before a regulator does.

Want more breakdowns like this one as they happen? Join Supplements Scaling Insiders, our free community for supplement brand owners scaling on Amazon, Meta, and TikTok Shop.

Firaas @ eBrandX

Firaas @ eBrandX

Wellness, Nutrition & Supplement Brands Growth | ★4.9/5 | 9+ Years | 75K+ Community Built | 300+ Clients

LinkedIn logo icon
Instagram logo icon
Youtube logo icon
Back to Blog

Get Strategy Call For FREE